Blitzer, Clancy & Company
Blitzer, Clancy & Company provides buy-side and sell-side M&A advisory, strategic advisory, and growth consulting services. Its disclosed coverage includes life sciences, industrial technology, manufacturing, real estate services, aerospace and defense, and related areas, with activity spanning North America, Europe, and Asia Pacific.
The firm publicly presents an advisory model rather than a principal-investment or portfolio-ownership model.
It represents buyers and sellers, advises strategic, private-equity, and venture-capital counterparties, and serves clients ranging from the Middle Market to Fortune 500 multinationals.[1][2][3][8][9]
What does Blitzer, Clancy & Company do?
Blitzer, Clancy & Company operates as an independent M&A and strategic advisory firm. Its official materials identify Michael Blitzer and James E. Clancy as co-founders and partners. The firm describes its work as serving entrepreneurial sellers, buyers, and growth-focused companies around the globe.[1][2]
The firm provides buy-side and sell-side M&A advisory and strategic advisory services. Its buy-side work includes target identification, content generation, execution, and management-team support. Strategic advisory services include positioning, target solicitation, and selection of equity partners or investors.[3]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring Blitzer, Clancy & Company?
An owner evaluating a sale or strategic partnership can assess the firm’s disclosed sell-side capabilities, sector experience, international activity, and approach to maintaining a consistent advisory team. Direct discussions should establish the proposed engagement team’s comparable experience, buyer-access process, fee mechanics, conflicts policy, valuation methodology, regulatory structure, and expected process timeline. The public services page does not establish universal fee or transaction-size parameters, so those terms should be confirmed for the proposed mandate.[2][3][4][5]
What legal entity would sign the engagement, and what firm-level broker-dealer, investment-adviser, or other regulatory status applies
What are the proposed retainer, success fee, minimum fee, expense reimbursement, exclusivity, termination, and tail provisions
What revenue, EBITDA, enterprise-value, or transaction-size profiles does the firm currently prioritize by sector
What size transactions and clients does Blitzer, Clancy & Company focus on?
Publicly identified areas of expertise include life sciences, commercial real estate services, information technology, manufacturing, and instrumentation. The industrial practice covers aerospace and defense, advanced manufacturing, and industrial technology, including automation and controls, test and measurement, flow and process control, motion control, and industrial software.
The commercial and industrial real estate services practice includes facility and workplace operations, engineering and capital projects, industrial and manufacturing services, aviation and airport services, healthcare and critical environments, education and campus operations, commercial property operations, and experiential design.[4][5][6]
- Blitzer, Clancy & Company represented Cureline in ABS Bio’s acquisition of Cureline, announced January 6, 2026.
- The firm represented Downstream and GA in Elevate’s strategic acquisitions announced December 18, 2025.
- The firm advised Analytical Biological Services in 3 Boomerang Capital’s strategic growth investment announced June 24, 2024.
- The firm advised Diamond-Roltran in HOERBIGER’s acquisition of Diamond-Roltran, announced March 21, 2024.
The firm’s public transaction model is advisory. It represents buy-side and sell-side parties and advises strategic, private-equity, and venture-capital counterparties rather than presenting itself as a principal portfolio owner.[1]
What does Blitzer, Clancy & Company publicly disclose about fees, process and engagement terms?
The cited services page does not publish a universal fee schedule, success-fee percentage, minimum fee, termination fee, tail period, or engagement-term schedule. That page also does not publish a universal minimum revenue, EBITDA, enterprise-value, or transaction-size threshold.
The cited ABS Bio-Cureline announcement does not disclose transaction value, consideration, financing terms, or Blitzer, Clancy & Company’s engagement economics.[3][9]
Official company materials describe Blitzer, Clancy & Company as providing investment banking, M&A advisory, growth consulting, and strategic advisory services. The sources cited for this profile do not establish a specific broker-dealer, investment-adviser, or other firm-level regulatory registration status. That status should be verified directly with the firm and applicable regulators before reliance.[2]
The firm states that it operates as an extension of the management team and maintains a consistent advisory team from the beginning through the end of an engagement. Its buy-side service description identifies target identification, content generation, execution, and management-team support as parts of that offering.[2][3]
Questions to ask before hiring Blitzer, Clancy & Company
What legal entity would sign the engagement, and what firm-level broker-dealer, investment-adviser, or other regulatory status applies?
What are the proposed retainer, success fee, minimum fee, expense reimbursement, exclusivity, termination, and tail provisions?
What revenue, EBITDA, enterprise-value, or transaction-size profiles does the firm currently prioritize by sector?
Which members of the team would lead the mandate, and how many comparable transactions have they completed recently?
How would the firm manage conflicts when representing buyers, sellers, investors, or strategic parties in adjacent sectors?
Which international buyers or investors would be approached, and what information would be shared before confidentiality protections are in place?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Services / capabilities
- Industry / market focus
- Industry / market focus
- Industry / market focus
- Geography / market coverage
- Transaction size / criteria
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.